Warts – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Warts – Pipeline Review, H1 2017’, provides an overview of the Warts pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Warts, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Warts and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Warts

The report reviews pipeline therapeutics for Warts by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Warts therapeutics and enlists all their major and minor projects

The report assesses Warts therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Warts

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Warts

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Warts pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3M Drug Delivery Systems

Aclaris Therapeutics Inc

Agilvax Inc

Aviragen Therapeutics Inc

Biogenomics Ltd

BioMAS Ltd

Cutanea Life Sciences Inc

Cytovation AS

Foamix Pharmaceuticals Ltd

G&E Herbal Biotechnology Co Ltd

Laboratories Ojer Pharma SL

LEO Pharma A/S

Nielsen Biosciences Inc

Novan Inc

Novartis AG

Promius Pharma LLC

RXi Pharmaceuticals Corp

Tamir Biotechnology Inc

Verrica Pharmaceuticals Inc

Zydus Cadila Healthcare Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Warts - Overview

Warts - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Warts - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Warts - Companies Involved in Therapeutics Development

3M Drug Delivery Systems

Aclaris Therapeutics Inc

Agilvax Inc

Aviragen Therapeutics Inc

Biogenomics Ltd

BioMAS Ltd

Cutanea Life Sciences Inc

Cytovation AS

Foamix Pharmaceuticals Ltd

G&E Herbal Biotechnology Co Ltd

Laboratories Ojer Pharma SL

LEO Pharma A/S

Nielsen Biosciences Inc

Novan Inc

Novartis AG

Promius Pharma LLC

RXi Pharmaceuticals Corp

Tamir Biotechnology Inc

Verrica Pharmaceuticals Inc

Zydus Cadila Healthcare Ltd

Warts - Drug Profiles

(digoxin + furosemide) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

854-A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Albicin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AX-03 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BTA-074 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CB-0602 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CyPep-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DFD-05 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FIT-039 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

furosemide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

human papillomavirus [serotypes 6, 11] (bivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

human papillomavirus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hydrogen peroxide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

imiquimod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

imiquimod SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ingenol mebutate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

interferon alfa-2b - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LFX-453 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omiganan pentahydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

povidone iodine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PP-210 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ranpirnase - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Samcyprone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SB-206 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRT-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VP-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Warts - Dormant Projects

Warts - Discontinued Products

Warts - Product Development Milestones

Featured News & Press Releases

Nov 29, 2016: Novan Announces Statistically Significant Phase 2 Clinical Trial Results for SB206

Aug 18, 2016: Aclaris Therapeutics Announces Positive Results in Phase 2 Clinical Trial of A-101 for Treatment of Common Warts

Jul 30, 2016: Cytovation granted EU patent for its lead product, CyPep-1, for the treatment of cutaneous warts

Jul 21, 2016: RXi Pharmaceuticals to Present at the 2016 Summer Meeting of the American Academy of Dermatology

May 10, 2016: Novan to Present Anti-viral Data for Nitric Oxide Product Candidate SB206

Dec 21, 2015: RXi Pharmaceuticals Announces the Initiation of a Phase 2 Trial in Dermatology with Samcyprone for Cutaneous Warts

Dec 07, 2015: Aclaris Therapeutics Initiates Phase 2 Clinical Trial of A-101 for Treatment of Common Warts

May 13, 2015: VCRO Announces Phase II IND Package in Common Technical Document (CTD) Accepted by the USA FDA

May 13, 2015: VCRO Announces Phase II IND Package in Common Technical Document (CTD) Accepted by the USA FDA

Oct 26, 2012: South Africa, first to grant IP protection in anti-warts

May 07, 2003: Henderson Morley: Signed Licensing Agreement

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Warts, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Warts – Pipeline by 3M Drug Delivery Systems, H1 2017

Warts – Pipeline by Aclaris Therapeutics Inc, H1 2017

Warts – Pipeline by Agilvax Inc, H1 2017

Warts – Pipeline by Aviragen Therapeutics Inc, H1 2017

Warts – Pipeline by Biogenomics Ltd, H1 2017

Warts – Pipeline by BioMAS Ltd, H1 2017

Warts – Pipeline by Cutanea Life Sciences Inc, H1 2017

Warts – Pipeline by Cytovation AS, H1 2017

Warts – Pipeline by Foamix Pharmaceuticals Ltd, H1 2017

Warts – Pipeline by G&E Herbal Biotechnology Co Ltd, H1 2017

Warts – Pipeline by Laboratories Ojer Pharma SL, H1 2017

Warts – Pipeline by LEO Pharma A/S, H1 2017

Warts – Pipeline by Nielsen Biosciences Inc, H1 2017

Warts – Pipeline by Novan Inc, H1 2017

Warts – Pipeline by Novartis AG, H1 2017

Warts – Pipeline by Promius Pharma LLC, H1 2017

Warts – Pipeline by RXi Pharmaceuticals Corp, H1 2017

Warts – Pipeline by Tamir Biotechnology Inc, H1 2017

Warts – Pipeline by Verrica Pharmaceuticals Inc, H1 2017

Warts – Pipeline by Zydus Cadila Healthcare Ltd, H1 2017

Warts – Dormant Projects, H1 2017

Warts – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Warts, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports